Список литературы

1. [1] "Воробьев А.И. Абдулкадыров К.М., Хорошко Н.Д., Диагностика и терапия хронического миелолейкоза. 2011; Москва, с. 53."

2. [2] "Куликов С.М., Виноградова О.Ю., Челышева Е.Ю. и др. Заболеваемость хроническим миелолейкозом в 6 регионах России по данным популяционного исследования 2009 - 2012 гг. Терапевтический архив. 2014; 86(7): 24 - 30."

3. [3] "Голенков А.К. Высоцкая Л.Л., Трифонова Е.В. Эффективность программы лечения хронического миелолейкоза гливеком в широкой клинической практике. Альманах клинической медицины МОНИКИ. 2008; (18): 9 - 13."

4. [4] "Стахина О.В., Туркина А.Г., Гусарова Г.А., Виноградова О.Ю., Захарова Е.С., Абакумов Е.М, и др. Отдаленные результаты выживаемости больных в поздней хронической фазе Ph+ хронического миелолейкоза при лечении иматиниб мезилатом (). Вестник гематолог."

5. [5] "Deininger M., O'Brien S.G., Guilhot F., Goldmanj.M., HochhausA., HughesT.P., etal. International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnos."

6. [6] "Kantarjian H.M., Talpaz M., O'Brien S., Jones D., Giles F., Garcia-Manero G., et al. Survival benefit with imatinib mesylate versus interferon-a based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. Blood. 2006; 108(6): 1835 - 40."

7. [7] "O'Brien S.G., Guilhot F., Goldman J.M., Hochhaus A., Hughes T.P., Radich J.P., et al. International Randomized Study of Interferon Versus STI571 (IRIS) 7-Year Follow-up: Sustained Survival, Low Rate of Transformation and Increased Rate of Major Molecular."

8. [8] Абдулкадыров К.М., Ломайа Е.Г., Шуваев В.А., Абдулкадырова А.С., Удальева В.Ю., Усачева Е.И., "Оценка выживаемости, достижения молекулярного, цитогенетического ответов у пациентов с хроническим миелолейкозом в хронической фазе, получающих терапию Иматинибом: данные девятилетнего популяционного наблюдения больных хроническим миелолейкозом Санкт-Пете," Вестник гематологии, vol. 5, по. 2, р. 5, 2010.

9. [9] "Шуваев В.А. Абдулкадырова А.С., Мартынкевич И.С., Удальева В.Ю., Усачева Е.И., Зотова И.И., и др. Опыт лечения хронического миелолейкоза в Санкт-Петербурге. Вестник Гематологии. 2011; 7(1): 43."

10. [10] "Туркина А.Г. Хельман Р., Поспелова Т.И., Виноградова О.Ю., Ионова Т.И. Практические аспекты терапии хронического миелолейкоза в хронической фазе. Материалы выступлений Всероссийского конгресса гематологов, Москва, 3 июля 2012 г. Онкогематология. 2012; 201."

11. [11] "leCoutre P., Ottmann O.G., Giles F., Kim D.-W., Cortes J., Gattermann N., etal. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic mye."

12. [12] "Mauro M., Cervantes F., Lipton J.H., Matloub Y., Sinha R., Stone R.M. Dasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML-CP) with resistance or intolerance to imatinib (START-C). Journal of Clinical Oncology. 2008."

13. [13] Домрачева Е.В., Виноградова О.Ю., Асеева Е.А., Воронцова А.В., Туркина А.Г., "Влияние различных хромосомных аномалий в Ph-позитивных клетках костного мозга на течение хронического миелолейкоза при терапии ингибиторами тирозинкиназ," Онкогематология, vol. 4, pp. 24 - 34, 2012.

14. [14] Хорошко Н.Д., Виноградова О.Ю., Асеева Е.А., Неверова А.Л., Туркина А.Г., "Клональные хромосомные аномалии в Ph-негативных клетках у больных хроническим миелолейкозом, получающих терапию ингибиторами тирозинкиназ," Клиническая онкогематология, vol. 4, pp. 361 - 367, 2010.

15. [15] Домрачева Е.В. и соавт. "Роль цитогенетических исследований при лечении хронического миелолейкоза ингибиторами тирозинкиназ," Гематология и трансфузиология, vol. 52, по. 2, pp. 25 - 28, 2007.

16. [16] "Туркина А.Г., Домрачева Е.В., Воронцова А.В., Асеева Е.А., Виноградова О.Ю., Хорошко Н.Д. и др. Трисомия 8 хромосомы в Ph-негативных клетках костного мозга у больных хроническим миелолейкозом при лечении ингибиторами BCR-ABL тирозинкиназ. Терапевтический."

17. [17] "Kantarjian H.M., Shah N.P., Cortes J.E., Baccarani M., AgarwalM.B., UndurragaM.S., etal. Dasatinib or imatinib in newly diagnosed chronic phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2012 119: 1123."

18. [18] "Kantarjian H., Hochhaus A., Saglio G. et al Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomisedENESTnd trial Lancet Oncol 2011; 12: 841 - 51"

19. [19] "Baccarani M., Deininger M.W., Rosti G., Hochhaus A., Soverini S., Apperley J.F., et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013; 122(6): 872 - 84."

20. [20] "Baccarani M., Saglio G., Goldman J., Hochhaus A., Simonsson B., Appelbaum F., et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006; 108(6): 1809 - 20."

21. [21] "Baccarani M., Pileri S., Steegmann J.-L., M. Muller, S. Soverini, M. Dreyling, et al. Chronic myeloid leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2012; 23(s7): 72 - 7."

22. [22] "Radich, J.P. NCCN Clinical Practice Guidelines in Oncology. Chronic Myelogenous Leukemia, version 1.2016/J.P. Radich, M.W. Deininger, C.N. Abbound, et al.//Natl. Compr. Cancer Netw. (NCCN). - 2016. - Режим доступа: http//www.nccn.org."

23. [23] "Электронный ресурс. Оксфордский центр доказательной медицины. Уровни доказательности (Март 2009. Разработали Боб Филипс К.Б., Дейв Сакетт, Доуг Баденох, Шарон Штраус, Брайен Хайнес, Мартин Давес в ноябре 1998. Режим доступа: http://www.cebm.net/oxford-cen."

24. [24] "Абдулкадыров К.М., Блинов М.Н., Щербакова Е.Г., Сорокин Е.М., Шляпочникова Г.П., Куравлева В.В., и др. Дифференциальная диагностика идиопатического миелофиброза и хронического миелолейкоза. 1985; Ленинград, с. 43."

25. [25] "Абдулкадыров К.М., Клиническая гематология: справочник. 2006; Санкт-Петербург: Питер: Питер Принт, с. 748."

26. [26] "Воробьев А.И. Руководство по гематологии. М. Ньюдиамед. 2003; 3: с. 9 - 15."

27. [27] "Hoffmann V., Baccarani M., Hasford J. et al. The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries. Leukemia. 2015; 29: 1336 - 43."

28. [28] "Абдулкадыров К.М. Туркина А.Г., Хорошко Н.Д. Рекомендации по диагностике и терапии хронического миелолейкоза. 2013; Санкт-Петербург, Москва, с. 80."

29. [29] Абдулкадыров К.М., Абдуллаев А.О, Авдеева Л.Б., Афанасьев Б.В., Виноградова Е.Ю., Виноградова О.Ю., "Федеральные клинические рекомендации по диагностике и терапии хронического миелолейкоза," Вестник гематологии, vol. 9, по. 3, pp. 4 - 41, 2013.

30. [30] "Sokal J., Cox E., Baccarani M., Tura S., Gomez G., Robertson., et al. Prognostic discrimination in good-risk' chronic granulocytic leukemia. Blood. 1984; 63(4): 789 - 99."

31. [31] "Hasford J., Baccarani M., Hoffmann V., Guilhot J., Saussele S., Rosti G., et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood. 2011; 118(3): 686 - 9."

32. [32] J. Hasford, M. Pfirrmann, R. Hehlmann, N. C. Allan, M. Baccarani, J. C. Kluin-Nelemans, G. Alimena, J. L. Steegmann, and H. Ansari, "A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group,"/Natl Cancer Inst, vol. 90, no. 11, pp. 850 - 858, 1998.

33. [33] M. Pfirrmann, M. Baccarani, S. Saussele, J. Guilhot, F. Cervantes, G. Ossenkoppele, V. S. Hoffmann, F. Castagnetti, J. Hasford, R. Hehlmann, and B. Simonsson, Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia, no. November 2015. NaturePublishingGroup, 2015.

34. [34] Аксенова Е.В. Крутов А.А., Солдатова И.Н., Челышева Е.Ю., Туркина А.Г., Хорошко Н.Д., "Молекулярный мониторинг у пациентов с хроническим миелолейкозом: корреляция с цитогенетическим ответом, прогностическое значение, оценка ответа на терапию," Клиническая онкогематология, vol. 3, по. 2, pp. 151 - 159, 2010.

35. [35] "Зарицкий А.Ю. Виноградова О.Ю., Лория С.С. и др. Факторы прогноза при терапии иматиниба мезилатом у больных в хронической фазе Ph-позитивного хронического миелолейкоза: данные многоцентрового нерандомизированного исследования в России. Терапевтический арх."

36. [36] "Branford S., Lawrence R., Grigg A., Seymour J.F., Schwarer A., Arthur C., et al. Long Term Follow up of Patients with CML in Chronic Phase Treated with First-Line Imatinib Suggests That Earlier Achievement of a Major Molecular Response Leads to Greater St."

37. [37] "Туркина А.Г. Хорошко Н.Д. и др., Практические рекомендации по лечению больных хроническим миелолейкозом. М. Тверь: Триада, 2005; с. 43."

38. [38] "tablets G.i.m., Imatinib prescribing information. 2007: East Hanover, New Jersey, Novartis Pharmaceuticals Corporation, Revised November."

39. [39] "Griffin J.D., Weisberg E.L. Simultaneous Administration of AMN107 and Imatinib in the Treatment of Imatinib-Sensitive and Imatinib-Resistant Chronic Myeloid Leukemia. ASH Abstracts. 2005; 106(11): 694."

40. [40] "Jabbour E., Cortes J., Giles F., O'Brien S., Kantarijan H. Drug evaluation: Nilotinib - a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyond. IDrugs. 2007; 10(7): 468 - 79."

41. [41] "TASIGNA(R)(nilotinib) Summary of Product Characteristics. Basel S.N.P.A. 2011."

42. [42] "Giles F.J., Rosti G., Beris P., Clark R.E., le Coutre P., Mahon F.-X., et al. Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study. Expert Review of Hematology. 2010; 3(6); 665 - 73."

43. [43] "Tokarski J.S., Newitt J.A., Chang C.Y.J., Cheng J.D., Wittekind M., Kiefer S.E., et al. The Structure of Dasatinib (BMS-354825) Bound to Activated ABL Kinase Domain Elucidates Its Inhibitory Activity against Imatinib-Resistant ABL Mutants. Cancer Research."

44. [44] "Porkka K., Koskenvesa P., Lundan T., Rimpilainen J., Mustjoki S., Smykla R., et al. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood. 2008; 112(4): 1005 - 12."

45. [45] "Hochhaus A, et al, Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trialLeukemia 2016, 30(5): 1044 - 54;"

46. [46] "Powell B.L., Khoury H.J., Lipton J.H., Rizzieri D.A., Williams D., Turner A.R. Nilotinib Responses and Tolerability Confirmed in North American Patients with Chronic Myeloid Leukemia (CML) From ENACT (Expanding Nilotinib Access in Clinical Trials). ASH Ab."

47. [47] "Hochhaus A., Kantarjian H.M., Baccarani M., Lipton J.H., Apperley J.F., Druker B.J., et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood. 2007; 109(6): 2."

48. [48] "Guilhot F., Apperley J., Kim D.-W., Bullorsky E.O., Baccarani M., Roboz G.J., et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or - intolerant chronic myeloid leukemia in accelerated phase. Bloo."

49. [49] "Cortes J., Rousselot P., Kim D.-W., Ritchie E., Hamerschlak N., Coutre S., et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or - intolerant chronic myeloid leukemia in blast crisis. Blood. 2007; 10."

50. [50] "Brummendorf T.H. et.al. Bosutinib (BOS) as third-line therapy for chronic phase (CP) chronic myeloid leukemia (CML) following failure with imatinib (IM) and dasatinib (DAS) or nilotinib (NIL). j Clin Oncol. 2011; 29 (suppl): abstr 6535."

51. [51] "Gambacorti-Passerini, et al. Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up. American Journal of Hematology. 2014: 89(7): 732 - 742."

52. [52] "Электронный ресурс. Режим доступа: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/2033411bl.pdf."

53. [53] "Steegmann J.L., Baccarani M., Breccia M., et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia Leukemia 2016 Apr 28. doi: 10.1038/leu.2016.104. [Epub ahead of print]."

54. [54] "Tefferi A., Letendre L. Nilotinib treatment-associated peripheral artery disease and sudden death: Yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia. American Journal of Hematology. 2011; 86(7): 610 - 1."

55. [55] "Krauth M.-T., Herndlhofer S., Schmook M.-T., Mitterbauer-Hohendanner G., Schlogl E., Valent P. Extensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100 mg or 50 mg daily. Haematologica. 2011; 96(1): 163."

56. [56] "Ouintas-Cardama A., Kantarjian H., O'Brien S., Borthakur G., Bruzzi Munden R.et al. Pleural Effusion in Patients With Chronic Myelogenous Leukemia Treated With Dasatinib After Imatinib Failure. Journal of Clinical Oncology. 2007; 25(25): 3908 - 14."

57. [57] "Ouintas-Cardama A., Han X., Kantarjian H., Cortes J. Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. Blood. 2009; 114(2): 261 - 3."

58. [58] "Справочник лекарственных средств. VIDAL. Описание лекарственного препарата БОСУЛИФ (BOSULIF). Режим доступа: www.vidal.ru/drugs/bosulif_43441."

59. [59] "Soverini S., Colarossi S., Gnani A., Rosti G., Castagnetti F., Poerio A., et al. Contribution of ABL Kinase Domain Mutations to Imatinib Resistance in Different Subsets of Philadelphia-Positive Patients: By the GIMEMA Working Party on Chronic Myeloid Leuk."

60. [60] "Soverini S., Gnani A., Colarossi S., Castagnetti F., Abruzzese E., Paolini S., et al. Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associat."

61. [61] S. Soverini, A. Hochhaus, F. E. Nicolini, F. Gruber, T. Lange, G. Saglio, F. Pane, M.C. Mu, T. Ernst, G. Rosti, K. Porkka, M. Baccarani, N.C. P. Cross, and G. Martinelli, "Review article BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet," Blood, vol. 118, no. 5, pp. 1208 - 1215, 2011.

62. [62] "O'Hare T., Walters D.K., Stoffregen E.P., Jia T., Manley P.W., Mestan J., et al. In vitro Activity of Bcr-Abl Inhibitors AMN107 and BMS-354825 against Clinically Relevant Imatinib-Resistant Abl Kinase Domain Mutants. Cancer Research. 2005; 65(11): 4500 - 5."

63. [63] R. R. Sara Redaelli, Rocco Piazza, M.M. Vera Magistroni, Pietro Perini, and and C. Gambacorti-Passerini, "Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants," Clin. Oncol, vol. 27, no. 3, pp. 468 - 469, 2008.

64. [64] "Электронный ресурс. Режим доступа: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm332252.htm."

65. [65] "O'Hare T., Shakespeare W.C., Zhu X., Eide C.A., Rivera V.M., Wang F., et al. AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance. Cancer cell. 2009; 16(5): 401 - 12."

66. [66] "Hochhaus A S.N., Cortes JE, Dasatinib versus imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): DASISION 3-year follow-up. Program and abstracts of the 2012 Annual Meeting of the American Society of Clinical Oncology. 2012."

67. [67] "Kantarjian H.M., Kim D.-W., Issaragrisil S., Clark R.E., Reiffers J. Enestnd 4-Year (y) Update: Continued Superiority of Nilotinib Vs Imatinib in Patients (pts) with Newly Diagnosed Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chroni."

68. [68] "Wei G., Rafiyath S., Liu D. First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib. Journal of Hematology & Oncology. 2010; 3(1): 47."

69. [69] "Челышева Е.Ю. Туркина А.Г., Мисюрин А.В., Захарова А.В. Раннее выявление цитогенетического рецидива при динамическом исследовании уровня BCR-ABL транскрипта у больного хроническим миелолейкозом. Гематология и трансфузиология. 2007; 52(2): 50 - 1."

70. [70] "Hughes T., Deininger M., Hochhaus A., Branford S., Radich J., Kaeda J., et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcript."

71. [71] "Pavlovsky C., Giere I., Lombardi V., Negri P., Moiraghi B., Garcia J., et al. Monitoring Minimal Residual Disease by Quantitative PCR in Chronic Myeloid Leukemia Patients in Complete Cytogenetic Remission. ASH Abstracts. 2008; 112(11): 4272."

72. [72] "Press R.D., Love Z., Tronnes A.A., Yang R., Tran T., Mongoue-Tchokote S., et al. BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate treated patients with CML. Blood. 2006; 10."

73. [73] "de Padua Silva L., Cortes J., Jabbour E., Giralt S., Kebriaei P., O'Brien S., et al. Novel Tyrosine Kinase Inhibitor Therapy Before Allogeneic Stem Cell Transplantation in Patients with Chronic Myeloid Leukemia. ASH Abstracts. 2008; 112(11): 2154."

74. [74] "Электронный ресурс. Common Terminology Criteria for Adverse Events v4.0 (CTCAE). Publish Date: May 28, 2009, NIH Publication No. 09-5410. Режим доступа: http://evs.nci.nih.gov/ftpl/CTCAE/CTCAE_4.03_2010-06-14_OuickReference_5x7.pdf."

75. [75] "Гусарова Г.А., Туркина А.Г., Воронцова А.В. и др. Отдаленные результаты терапии дазатинибом и анализ особенностей течения плеврального выпота у больгных в поздней хронической фазе хронического миелолейкоза после неудачи лечения иматинибом. Бюллетень Сибир."

76. [76] "Larson R., le Coutre P., Reiffers j., et al. Comparison of nilotinib and 1674 imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) ENESTnd beyond one year. J Clin Oncol. 2010; 28(15s): abstr 6501."

77. [77] "Rea D., Mirault T., Cluzeau T., et al. Early onset hypercholesterolemia induced by the second generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemia. Haematologica. 2014; 99(7): 1197 - 1203."

78. [78] "Aichberger K.J., Herndlhofer S., Schernthaner G.H., et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol. 2011; 86(7): 533 - 9."

79. [79] "Hiwase D.K., Yeung D.T., Carne L. Hypercholesterolemia in imatinib intolerant/resistant CML-CP patients treated with nilotinib: a retrospective analysis. Blood. 2013; 122: 1503."

80. [80] "Диагностика и коррекции нарушений липидного обмена с целью профилактики и лечения атеросклероза, Российские рекомендации. V пересмотр. Москва. 2012 год."

81. [81] "Pye S.M., Cortes j., Ault P., Hatfield A., Kantarjian H., Pilot R., et al. The effects of imatinib on pregnancy outcome. Blood. 2008; 111(12): 5505 - 8."

82. [82] "Mattei D., Feola M., Orzan F., Mordini N., Rapezzi D., Gallamini A. Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient. Bone MarrowTransplant. 2009; 43(12): 967 - 8."

83. [83] "Dumitrescu D., Seek C., ten Freyhaus H., Gerhardt F., Erdmann E., Rosenkranz S. Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia. Eur Respir J. 2011; 38(1): 218 - 20."

84. [84] "Montani D., Bergot E., Gunther S., Savale L., Bergeron A., Bourdin A., et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation. 2012; 125(17): 2128 - 37."

85. [85] "Shah N.P., Wallis N., Farber H.W. Clinical feature of pulmonary arterial hypertension in patients receiving dasatinib. Am J Hematol. 2015; 90 (11): 1060 - 4."

86. [86] "Bergeron A., Bergot E., Vile la G., Ades L., Devergie A., Esperou H., et al. Hypersensitivity pneumonitis related to imatinib mesylate. J Clin Oncol. 2002; 20(20): 4271 - 2."

87. [87] "Ma C.X., Hobday T.J., Jett J.R. Imatinib mesylate-induced interstitial pneumonitis. Mayo Clin Proc. 2003; 78(12): 1578 - 9."

88. [88] "Rajda J., Phatak P.D. Reversible drug-induced interstitial pneumonitis following imatinib mesylate therapy. 1 Am J Hematol. 2005; 79(1): 80 - 1."

89. [89] "Go S.W., Kim B.K., Lee S.H., Kim T.J., Huh J.Y., Lee J.M., et al. Successful rechallenge with imatinib in a patient with chronic myeloid leukemia who previously experienced imatinib mesylate induced pneumonitis. Tuberculosis and respiratory diseases. 2013."

90. [90] "Tamura M., Saraya T., Fujiwara M., Hiraoka S., Yokoyama T., Yano K., et al. High-re solution computed tomography findings for patients with drug-induced pulmonary toxicity, with special reference tohypersensitivity pneumonitis-like patterns in gemcitabine-."

91. [91] "Лазарева О.В., Костина И.Э., Туркина А.Г. Лекарственно-индуцированный пневмонит: редкое осложнение терапии иматиниба мезилатом у больных хроническим миелолейкозом. Клиническаяонкогематология. 2010; 1(3): 47 - 52."

92. [92] "Radaelli F., Vener C., Ripamonti F., etal. Conjunctival hemorrhagic events 2087 associated with imatinib mesylate. Int J Hematol. 2007; 86(5): 390 - 3."

93. [93] "Berveiller P., Andreoli A., Mir O., Anselem O., Delezoide A.-L., Sauvageon H.,et al. A dramatic fetal outcome following transplacental transfer of dasatinib. Anti-Cancer Drugs. 2012; 23(7): 754 - 7."

94. [94] "Cortes J.E., Abruzzese E., Chelysheva E. The impact of dasatinib on pregnancy outcomes. AmJHematol. 2015; 90(12): 1111 - 5."

95. [95] "Сухих Г.Т., Давыдов М.И., Савченко В.Г. Репродуктивное здоровье женщин с онкогематологическими заболеваниями. Москва, 2012 г."

96. [96] "Russell M.A., Carpenter M.W., Akhtar M.S., Lagattuta T.F., Egorin M.J. Imatinib mesylate and metabolite concentrations in maternal blood, umbilical cord blood, placenta and breast milk. J Perinatol. 2000. 27(4): 241 - 3."

97. [97] "Breccia M., Cannella L., Montefusco E., Frustaci A., Pacilli M., Alimena G. Male patients with chronic myeloid leukemia treated with imatinib involved in healthy pregnancies: Report of five cases. Leukemia research. 2008; 32(3): 519 - 20."

98. [98] G. Marzocchi, F. Castagnetti, S. Luatti, C. Baldazzi, M. Stacchini, G. Gugliotta, M. Amabile, G. Specchia, M. Sessarego, U. Giussani, L. Valori, G. Discepoli, A. Montaldi, A. Santoro, L. Bonaldi, G. Giudici, A. M. Cianciulli, F. Giacobbi, F. Palandri, F. Pane, G. Saglio, G. Martinelli, M. Baccarani, G. Rosti, and N. Testoni, "Variant Philadelphia translocations: Molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA working party on CML analysis," Blood, vol. 117, no. 25, pp. 6793 - 6800, 2011.

99. [99] S. Luatti, F. Castagnetti, G. Marzocchi, C. Baldazzi, G. Gugliotta, I. Iacobucci, G. Specchia, L. Zanatta, G. Rege-Cambrin, M. Mancini, E. Abruzzese, A. Zaccaria, M. G. Grimoldi, A. Gozzetti, G. Ameli, M. A. Capucci, G. Palka, P. Bernasconi, F. Palandri, F. Pane, G. Saglio, G. Martinelli, G. Rosti, M. Baccarani, and N. Testoni, "Additional chromosomal abnormalities in Philadelphia-positive clone: Adverse prognostic influence on frontline imatinib therapy: A GIMEMA Working Party on CML analysis," Blood, vol. 120, no. 4, pp. 761 - 767, 2012.

100. [100] F. Castagnetti, N. Testoni, S. Luatti, G. Marzocchi, M. Mancini, S. Kerim, E. Giugliano, F. Albano, A. Cuneo, E. Abruzzese, B. Martino, F. Palandri, M. Amabile, I. Iacobucci, G. Alimena, F. Pane, G. Martinelli, G. Saglio, M. Baccarani, and G. Rosti, "Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML working party analysis," Clin. Oncol., vol. 28, no. 16, pp. 2748 - 2754, 2010.

101. [101] F. Mitelman, P.G. Nilson, and L. Brandt, "NON-RANDOM KARYOTYPIC EVOLUTION IN CHRONIC MYELOID LEUKEMIA," Int J Cancer., vol. 18, no. 1, pp. 24 - 30, 1976.

102. [102] F. Mitelman, "The cytogenetic scenario of chronic myeloid leukemia.," Lymphoma, vol. 11 Suppl 1, pp. 11 - 5, 1993.

103. [103] F. Guilhot, "Cytogenetics in CML: more important than you think," Blood, vol. 127, no. 22, pp. 2661 - 2662, Jun. 2016.

104. [104] A. Fabarius, A. Leitner, A. Hochhaus, M.C. Mu, B. Hanfstein, C. Haferlach, B. Schlegelberger, M. Jotterand, A. Reiter, S. Jung-munkwitz, U. Proetel, J. Schwaab, W. Hofmann, H. Einsele, A.D. Ho, C. Falge, K. Spiekermann, G.M. Baerlocher, M. Lauseker, M. Pfirrmann, and J. Hasford, "Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV," vol. 118, no. 26, pp. 6760 - 6769, 2011.

105. [105] W. Wang, J.E. Cortes, G. Tang, J.D. Khoury, S. Wang, C.E. Bueso-Ramos, J.A. DiGiuseppe, Z. Chen, H.M. Kantarjian, L.J. Medeiros, and S. Hu, "Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy.," Blood, vol. 127, no. 22, pp. blood-2016-01-690230, 2016.

106. [106] А. К. М. Мартынкевич И.С., Мартыненко Л.С., Иванова М.П., Огородникова Ю.С., Дзявго Л.А., Москаленко М.В., Усачева Е.И., Удальева В.Ю., Мачюлайтене Е.Р., Мазикова Ю.Ю., Богданова Ю.С., Гончарова О.Д., Криволуцкая М.Н., Поспелова Т.И., Лямкина А.С., "Дополнительные хромосомные аберрации у пациентов с хроническим миелолейкозом," Гематология и трансфузиология, vol. 52, по. 2, pp. 28 - 35, 2007.

107. [107] О.Ю. Виноградова, Е.А. Асеева, А.В. Воронцова, А.Г. Туркина, А.Л. Неверова, О.В. Лазарева, Е.Ю. Челышева, Г.А. Гусарова, Т.И. Колошейнова, Л.Ю. Колосова, С.Р. Горячева, М.В. Вахрушева, С.М. Куликов, И.А. Тищенко, Л.В. Дяченко, А.И. Удовиченко, Г.А. Алимова, Е.В. Клейна, Л.А. Гребенюк, М.Л. Коннова, С.Ю. Смирнова, Н.Д. Хорошко, and Е.В. Домрачева, "Влияние различных хромосомных аномалий в Ph-позитивных клетках костного мозга на течение хронического миелолейкоза при терапии ингибиторами тирозинкиназ," Онкогематология, vol. 4, pp. 24 - 34, 2012.

108. [108] M. Baccarani, M. W. Deininger, G. Rosti, A. Hochhaus, S. Soverini, J. F. Apperley, F. Cervantes, R. E. Clark, J. E. Cortes, H. Hjorth-Hansen, T. P. Hughes, H. M. Kantarjian, D.-W. Kim, R. a Larson, J. H. Lipton, G. Martinelli, J. Mayer, C. M. Martin, J.-L. Steegmann, J. M. Goldman, F. Guilhot, H. Hjorth-Hansen, T. P. Hughes, H. M. Kantarjian, D.-W. Kim, R. a Larson, J. H. Lipton, F.-X. Mahon, G. Martinelli, J. Mayer, M. C. Muller, D. Niederwieser, F. Pane, J.P. Radich, P. Rousselot, G. Saglio, S. Sauftele, C. Schiffer, R. Silver, B. Simonsson, J.-L. Steegmann, J. M. Goldman, and R. Hehlmann, "Review Article European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013," Blood, vol. 122, no. 6, pp. 872 - 884, 2013.

109. [109] M. W. N. Deininger, J. Cortes, R. Paquette, B. Park, A. Hochhaus, M. Baccarani, R. Stone, T. Fischer, H. Kantarjian, D. Niederwieser, C. Gambacorti-Passerini, C. So, I. Gathmann, J.M. Goldman, D. Smith, B.J. Druker, and F. Guilhot, "The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in Philadelphia chromosome-negative cells," Cancer, vol. 110, no. 7, pp. 1509 - 1519, 2007.

110. [110] S.-E. Lee, S.Y. Choi, J.-H. Bang, S.-H. Kim, E.-J. Jang, J.-Y. Byeun, J.E. Park, H.-R. Jeon, Y. J. Oh, M. Kim, and D.-W. Kim, "The long-term clinical implications of clonal chromosomal abnormalities in newly diagnosed chronic phase chronic myeloid leukemia patients treated with imatinib mesylate.," Cancer Genet., vol. 205, no. 11, pp. 563 - 71, 2012.

111. [111] Cortes J, Saglio G., Kantarjian H., Baccarani M., et al. Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naive Chronic Myeloid Leukemia Patients Trial. Journal Of Clinical Oncology, 34:20, 2016, 2333 - 2341. 107. Kantarjian, Giles F., Bhalla K., et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood 2011 117: 1141 - 1145.

112. [112] Kantarjian H, Talpaz M, O"Brien S et al. Dose escalation of imatinibmesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood 101(2), 473 - 475 (2003).

113. [113] Zonder JA, Pemberton P, Brandt H, Mohamed AN, Schiffer CA. The effect of dose increase of imatinibmesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment. Cancer Res. 9(6), 2092 - 2097 (2003).

114. [114] Marin D, Goldman JM, Olavarria E, Apperley JF. Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses. Blood 102(7), 2702 - 2703 (2003).

115. [115] Kantarjian H (http://www.ncbi.nlm.nih.gov/pubmed/?term=Kantarjian%20H%5BAuthor%5D&cauthor=true&cauthor_uid=19536906), Pasquini R (http://www.ncbi.nlm.nih.gov/pubmed/?term=Pasquini%20R%5BAuthor%5D&cauthor=true&cauthor_uid= 19536906), Levy V (http://www.ncbi.nlm.nih.gov/pubmed/?term=L%C3%A9vy%20V%5BAuthor%5D&cauthor=true&cauthor_uid= 19536906), Jootar S (http://www.ncbi.nlm.nih.gov/pubmed/?term=Jootar%20S%5BAuthor%5D&cauthor=true&cauthor_uid=19536906), Holowiecki J (http://www.ncbi.nlm.nih.gov/pubmed/?term=Holowiecki%20J%5BAuthor%5D&cauthor=true&cauthor_uid=19536906), Hamerschlak N (http://www.ncbi.nlm.nih.gov/pubmed/?term=Hamerschlak%20N%5BAuthor%5D&cauthor=true&cauthor_uid=19536906), Hughes T (http://www.ncbi.nlm.nih.gov/pubmed/?term=Hughes%20T%5BAuthor%5D&cauthor=true&cauthor_uid=19536906), Bleickardt E (http://www.ncbi.nlm.nih.gov/pubmed/?term=Bleickardt%20E%5BAuthor%5D&cauthor=true&cauthor_uid=19536906), Dejardin D (http://www.ncbi.nlm.nih.gov/pubmed/?term=Dejardin%20D%5BAuthor%5D&cauthor=true&cauthor_uid=19536906), Cortes 1 (http://www.ncbi.nlm.nih.gov/pubmed/?term=Cortes%20J%5BAuthor%5D&cauthor=true&cauthor_uid=19536906), Shah NP (http://www.ncbi.nlm.nih.gov/pubmed/?term=Shah%20NP%5BAuthor%5D&cauthor=true&cauthor_uid=19536906).Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant toimatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R)//Cancer. (http://www.ncbi.nlm.nih.gov/pubmed/19536906) 2009 Sep 15; 115(18): 4136 - 47).

116. [116] Hughes TP (http://www.ncbi.nlm.nih.gov/pubmed/?term=Hughes%20TP%5BAuthor%5D&cauthor=true&cauthor_uid=24532039), Hochhaus A (http://www.ncbi.nlm.nih.gov/pubmed/?term=Hochhaus%20A%5BAuthor%5D&cauthor=true&cauthor_uid=24532039), Kantarjian HM (http://www.ncbi.nlm.nih.gov/pubmed/?term=Kantarjian%20HM%5BAuthor%5D&cauthor=true&cauthor_uid=24532039), Cervantes F (http://www.ncbi.nlm.nih.gov/pubmed/?term=Cervantes%20F%5BAuthor%5D&cauthor=true&cauthor_uid=24532039), Guilhot F (http://www.ncbi.nlm.nih.gov/pubmed/?term=Guilhot%20F%5BAuthor%5D&cauthor=true&cauthor_uid=24532039), Niederwieser D (http://www.ncbi.nlm.nih.gov/pubmed/?term=Niederwieser%20D%5BAuthor%5D&cauthor=true&cauthor_uid=24532039), le Coutre PD (http://www.ncbi.nlm.nih.gov/pubmed/?term=le%20Coutre%20PD%5BAuthor%5D&cauthor=true&cauthor_uid=24532039), Rosti G (http://www.ncbi.nlm.nih.gov/pubmed/?term=Rosti%20G%5BAuthor%5D&cauthor=true&cauthor_uid=24532039), Ossenkoppele G (http://www.ncbi.nlm.nih.gov/pubmed/?term=Ossenkoppele%20G%5BAuthor%5D&cauthor=true&cauthor_uid=24532039), Lobo C (http://www.ncbi.nlm.nih.gov/pubmed/?term=Lobo%20C%5BAuthor%5D&cauthor=true&cauthor_uid=24532039) 0, Shibayama H (http://www.ncbi.nlm.nih.gov/pubmed/?term=Shibayama%20H%5BAuthor%5D&cauthor=true&cauthor_uid=24532039), Fan X (http://www.ncbi.nlm.nih.gov/pubmed/?term=Fan%20X%5BAuthor%5D&cauthor=true&cauthor_uid=24532039), Menssen HD (http://www.ncbi.nlm.nih.gov/pubmed/?term=Menssen%20HD%5BAuthor%5D&cauthor=true&cauthor_uid=24532039), Kemp C (http://www.ncbi.nlm.nih.gov/pubmed/?term=Kemp%20C%5BAuthor%5D&cauthor=true&cauthor_uid=24532039), Larson RA (http://www.ncbi.nlm.nih.gov/pubmed/?term=Larson%20RA%5BAuthor%5D&cauthor=true&cauthor_uid=24532039), Saglio G (http://www.ncbi.nlm.nih.gov/pubmed/?term=Saglio%20G%5BAuthor%5D&cauthor=true&cauthor_uid=24532039). Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily.//Haematologica. (http://www.ncbi.nlm.nih.gov/pubmed/24532039) 2014 Jul; 99(7): 1204 - 11